"label","description","rationale","id","name","uuid:ID","instanceType"
"","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","Study Design 1","af200978-6d72-44f5-8a5e-9b4318981177","StudyDesign"
